Study identifier:NL401611
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
What is the value of the use of validated questionnaire (Reflux Impact Scale) for predicting treatment success with PPI
Gastroesophageal Reflux Disease
-
No
-
All
938
Observational
18 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Jul 2008 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|